1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Geriatric Population Prone to Chronic Diseases
4.2.2 Increasing Number of Emergency Cases
4.2.3 Growing Demand for Lesser Duration in Hospitalization
4.2.4 Increasing Accessibility to Health Services and Surgeries
4.3 Market Restraints
4.3.1 Generic Competition for Almost all of the Halogenated Agents
4.3.2 Recent Patent Expiries
4.3.3 Side Effects of Inhaler Anesthesia Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Type
5.1.1 Desflurane
5.1.2 Sevoflurane
5.1.3 Isoflurane
5.1.4 Others
5.2 End User
5.2.1 Hospitals
5.2.2 Ambulatory Surgical Centers
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Halocarbon Products Corporation
6.1.2 Baxter
6.1.3 Hikma Pharmaceuticals PLC
6.1.4 Lunan Pharmaceutical Group Co. Ltd
6.1.5 Piramal Enterprises Limited
6.1.6 Jiangsu Hengrui Medicine Co. Ltd
6.1.7 Fresenius Kabi AG
6.1.8 AbbVie Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned
- Halocarbon Products Corporation
- Baxter
- Hikma Pharmaceuticals PLC
- Lunan Pharmaceutical Group Co. Ltd
- Piramal Enterprises Limited
- Jiangsu Hengrui Medicine Co. Ltd
- Fresenius Kabi AG
- AbbVie Inc.